Teamwork makes the dream work: The Tipline for 26 April 2023

Illumina and Grail were less than pleased when the Federal Trade Commission joined its EU counterpart in blocking their transaction. Fast forward past a US Chamber of Commerce lawsuit seeking to peer into US-EU discussions and a half-dozen Wall Street Journal editorials describing the FTC as pro-cancer, Illumina and Grail now get a win – albeit rather small – from cross-jurisdictional regulation. The FTC has stayed its order against the merger pending the companies’ appeal because of similar instructions from Brussels.

Unlock unlimited access to all Global Competition Review content